Pemrydi Rtu Injection
Product Images NDC 70121-2461

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemrydi Rtu (NDC 70121-2461). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Pemrydi Rtu Pemetrexed Injection 1)

Chemical structure diagram of pemetrexed disodium, showing its molecular framework with labeled atoms including sodium (Na) and water molecules indicating hydration (.2.5 H2O).*

FDA Label Image

23 (Pemrydi Rtu Pemetrexed Injection 10)

A Kaplan-Meier survival curve graph comparing survival probability over time (in months) between two groups: patients treated with PEMRYDI RTU plus Cisplatin (solid line) and patients treated with Cisplatin alone (dotted line). The graph includes a table showing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

1 (Pemrydi Rtu Pemetrexed Injection 11)

PEMRYDI RTU 100 mg/10 mL injection label showing pemetrexed disodium as the active ingredient in a 10 mg/mL intravenous single-dose vial. The label specifies administration undiluted, hazardous drug status, storage conditions, manufacturer Zydus Lifesciences Limited, and distributor Amneal Pharmaceuticals LLC.*

FDA Label Image

2 (Pemrydi Rtu Pemetrexed Injection 12)

Carton packaging for PEMRYDI RTU (pemetrexed injection) 100 mg/10 mL (10 mg/mL) intravenous injection by Amneal Pharmaceuticals LLC. The single-dose vial is indicated for intravenous infusion only, to be administered undiluted. The label includes concentration, dosage storage instructions, and manufacturer information from Zydus Lifesciences Limited, India.*

FDA Label Image

3 (Pemrydi Rtu Pemetrexed Injection 13)

PEMRYDI RTU 500 mg/50 mL injection label showing pemetrexed disodium as the active ingredient. It is an intravenous single-dose vial with a strength of 10 mg/mL. Label includes storage instructions, manufacturer Zydus Lifesciences Limited, and distributor Amneal Pharmaceuticals LLC. Warning states 'Administer Undiluted' and that it is a hazardous drug for prescription use only.*

FDA Label Image

4 (Pemrydi Rtu Pemetrexed Injection 14)

PEMRYDI RTU 500 mg/50 mL (10 mg/mL) injection label for pemetrexed disodium intravenous infusion. The label states single-dose vial usage, instructions to discard unused portion, and to administer undiluted. Manufactured by Zydus Lifesciences Limited and distributed by Amneal Pharmaceuticals LLC. Includes concentration note, barcode, and storage temperature guidance.*

FDA Label Image

5 (Pemrydi Rtu Pemetrexed Injection 15)

Label for PEMRYDI RTU (pemetrexed injection) 1000 mg/100 mL intravenous infusion, single-dose vial. Contains 10 mg/mL pemetrexed equivalent, manufactured by Zydus Lifesciences Limited in India and distributed by Amneal Pharmaceuticals LLC. Storage and dosage information included. Marked as hazardous drug and Rx only.*

FDA Label Image

6 (Pemrydi Rtu Pemetrexed Injection 16)

The packaging label for PEMRYDI RTU (pemetrexed injection) displays a concentration of 1000 mg/100 mL (10 mg/mL) in solution for intravenous infusion. The label specifies it as a single-dose vial, with instructions to discard any unused portion and administer undiluted. It is a hazardous drug manufactured by Zydus Lifesciences Limited and distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

12 (Pemrydi Rtu Pemetrexed Injection 2)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months. Two treatment arms are compared: P+P+C (PEMRYDI RTU with pembrolizumab and platinum chemotherapy) and P+C (PEMRYDI RTU with platinum chemotherapy and placebo). The chart includes a number at risk table corresponding to each time point for both treatment groups.*

FDA Label Image

13 (Pemrydi Rtu Pemetrexed Injection 3)

A survival probability graph comparing PEMRYDI RTU combined with Cisplatin (PC) versus Gemcitabine combined with Cisplatin (GC) over a 30-month period. The x-axis represents survival time in months, and the y-axis represents survival probability. A table below the graph lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

14 (Pemrydi Rtu Pemetrexed Injection 4)

A Kaplan-Meier survival curve graph comparing survival probability over time (in months) between two treatment groups: PEMRYDI RTU plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The graph includes a survival probability y-axis (0 to 1) and survival time x-axis (0 to 30 months). Below the graph is a table showing the number of patients at risk over time for both groups.*

FDA Label Image

15 (Pemrydi Rtu Pemetrexed Injection 5)

A survival probability curve graph comparing PEMRYDI RTU plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) over time in months. The x-axis represents survival time in months, and the y-axis shows survival probability from 0.0 to 1.0. Patient risk numbers are listed below the x-axis for both treatment groups at multiple time points.*

FDA Label Image

23 (Pemrydi Rtu Pemetrexed Injection 6)

A Kaplan-Meier survival curve chart comparing survival probability over time (months) between PEMRYDI RTU and placebo groups. The solid line represents PEMRYDI RTU, showing higher survival probabilities compared to the dotted placebo line. Below the graph, a table shows the number of patients at risk for each group at various time points up to 42 months.*

FDA Label Image

17 (Pemrydi Rtu Pemetrexed Injection 7)

A survival probability curve comparing PEMRYDI RTU injection to placebo over a 42-month period. The graph plots survival probability on the vertical axis against survival time in months on the horizontal axis and includes patient numbers at risk for both PEMRYDI RTU and placebo groups under the timeline.*

FDA Label Image

18 (Pemrydi Rtu Pemetrexed Injection 8)

A survival curve graph comparing survival probability over time (months) between PEMRYDI RTU and placebo groups. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis. Two curves represent PEMRYDI RTU (solid line) and placebo (dotted line). Below the graph is a table listing the number of patients at risk for each group at multiple time points.*

FDA Label Image

22 (Pemrydi Rtu Pemetrexed Injection 9)

A survival curve graph comparing the survival probability over time (in months) between PEMRYDI RTU injection and placebo groups. Below the graph, a table shows the number of patients at risk at various time points for both PEMRYDI RTU and placebo groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.